Schedule a meeting
Market opportunity

Everyone serves the 12% — we serve the 88%

Arcus Medical targets the vast underserved population of women seeking minimally invasive pelvic organ prolapse care — those avoiding surgery due to cost, recovery time, and stigma.

Competitive landscape

Where everyone else competes — and where we dominate

12%

Traditional market — surgical

  • FDA ban on transvaginal mesh eliminated a primary treatment option.
  • Abdominal mesh only — mainly via robotic sacrocolpopexy.
  • Hospital-based, requiring specialized OR infrastructure.
  • Complex native-tissue reconstruction demanding advanced surgical expertise.
88%

Arcus TLT market — non-surgical

  • Vaginal pessaries — high discontinuation, uncomfortable.
  • Pelvic-floor therapies — Kegels, biofeedback, EM stimulation; high failure for moderate-to-severe POP.
  • Untreated patients living with symptoms due to limited options.
  • Arcus fills the gap with a simple, office-based, reimbursed solution.

A significant, defensible TLT advantage

While competitors fight over the saturated 12% surgical market, Arcus owns the massive 88% non-surgical segment with minimal direct competition.

7×

Larger addressable market

Versus the traditional surgical approach.

1st

First office-based solution

No modern in-office alternative exists today.

$900M

Untapped opportunity

In the underserved 88% segment.

Current market limitations

3,000 years of limited progress in treating POP

Vaginal pessaries

The oldest documented treatment, yet still widely used today.

  • Uncomfortable and require frequent maintenance
  • Low patient compliance and satisfaction
  • Outdated — doesn't address the root cause
  • Many women simply give up on treatment

Traditional surgery

Invasive procedures with significant barriers.

  • Requires a hospital setting and general anesthesia
  • High cost and extended recovery time
  • FDA removal of transvaginal mesh created a vacuum
  • Only 12% of affected women choose this option
The market need

A simple, office-based, minimally invasive solution — with immediate reimbursement

Exactly what Arcus TLT provides. Let's review the opportunity together.

Schedule a meeting Explore the technology